Algorae Pharmaceuticals (ASX: $1AI) Pre-clinical Study Results

Algorae Pharmaceuticals Limited (ASX: $1AI) has released positive results from in vitro pre-clinical studies for AI-116, a combination drug candidate for neurodegenerative disorders and dementia. The pre-clinical data demonstrates a neuroprotective effect of AI-116, surpassing the effect of the existing FDA registered drug for dementia, Donepezil. The cell viability increased by 20.1% for AI-116 compared to 2.1% for Donepezil in the pre-clinical studies.

Executive Commentary on AI-116 Pre-clinical Results

Professor Garrie Arumugam, the Principal Investigator, expressed optimism about the preliminary in vitro results, highlighting a clear pattern of neuronal cell protection and a synergistic method of action. Further investigations will focus on the implications of these findings and their potential impact on drug development. Additionally, RNA sequencing analysis will commence to assess the therapeutic mechanism associated with the use of AI-116, including evaluations for neuroinflammation, which plays a multifaceted role in the pathogenesis of neurodegenerative disorders and dementia.

Summary of Algorae Pharmaceuticals Announcement

Algorae Pharmaceuticals (ASX: $1AI) has reported promising pre-clinical results for AI-116, demonstrating its superior neuroprotective effect compared to the existing FDA registered drug for dementia, Donepezil. The company plans to conduct RNA sequencing analysis to further evaluate AI-116, including its impact on neuroinflammation. These results have been incorporated into provisional patent applications, aligning with the company's IP strategy. Algorae's commitment to addressing unmet medical needs is evident through its focus on developing novel treatments for neurodegenerative disorders and dementia. The outlook for AI-116 appears positive, with the potential to advance drug development in this critical therapeutic area.